文献库搜索 | GeneLibs

Cruz(A),Abreu(B),Mendes(C),Lemos(I),Freita... Discov Oncol 2026-04-17

...KRAS) alterations play a key role in cancer progression and patient survival. In this study, we investigated the influen...

Marchiò(S) NPJ Precis Oncol 2026-04-17

The recent breakthroughs in KRAS inhibition have converted a previously "undruggable" oncogene into a viable therapeutic...

Yi(Y),Hu(Y),Ren(S),Wu(Y),Chen(X),Lu(Y),Yu(... Respir Res 2026-04-17

...KRAS G12C-targeted therapies have transformed the treatment of KRAS G12C-mutant lung adenocarcinoma. However, acquired r...

Tsuchiya(T),Miyawaki(S),Ono(H),Hongo(H),Og... Transl Stroke Res 2026-04-18

...KRAS and BRAF mutations in sporadic bAVM endothelial cells (ECs) has fundamentally reshaped current understanding of bAV...

Zuppi(E),Addeo(P) J Gastrointest Surg 2026-07-00

...KRAS or BRAF) was reported in <40% of patients. The overall 90-day postoperative mortality rate was 4.0%. However, patie...

Hayward(S),Blaiss(C),Zacholski(EH),MacDona... Int J Gynecol Cancer 2026-05-00

...KRAS-mutated low-grade serous ovarian carcinoma, as evidenced by clinically meaningful response rates and manageable adv...

Li(Z),Li(P),Wu(S),Zhang(M),Zhang(F),Zheng(... Discov Oncol 2026-04-19

...KRAS (G13D) mutations (median: 11.0 months) compared with those without mutations (median: 6.30 months) or unknown genet...

Cao(D),Zhou(W),Li(Z),Lu(S),Hou(Z),Yu(L),Gu... Cancer Res 2026-07-15

...KRAS as a critical regulator of tDNA levels. Mutant KRAS promoted tDNA clearance by inducing the tetraspanin CD9, which ...

Liu(XJ),Nie(Q),Zhang(YS),He(J),Sun(XR),Cao... Bioorg Chem 2026-07-15

KRAS G12D, the most common oncogenic mutation of KRAS, represents a promising therapeutic target for solid tumors. Herei...

Samudrala(R),Bruggemann(L),Falls(Z),Mahaja... Expert Opin Drug Discov 2026-05-00

...KRAS G12C inhibitors to prevent drug resistance, pan-KRAS inhibitors capable of binding multiple KRAS mutations, and KRA...